Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti, MD, PhD, MRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses advances being made to improve outcomes following CAR-T therapy for patients with acute lymphoblastic leukemia (ALL) and lymphoma. Dr Chaganti first highlights the value of novel allogeneic products, which have demonstrated promising early results. Dr Chaganti also comments on the efficacy of the selective oral JAK1 inhibitor itacitinib as a prophylactic strategy to reduce the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) following CAR-T therapy. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.